The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Flu RNA Vaccines Market Research Report 2025
Synopsis
Flu RNA Vaccines, commonly known as flu vaccines, are designed to protect against the influenza virus. The influenza virus can cause respiratory illnesses ranging from mild to severe, and vaccination is an effective way to prevent or reduce the severity of flu infections.
Flu RNA Vaccines are an important public health measure to prevent the spread of the influenza virus and reduce the risk of severe illness, hospitalization, and death associated with the flu.
The global Flu RNA Vaccines market was valued at US$ 890 million in 2023 and is anticipated to reach US$ 1715.9 million by 2030, witnessing a CAGR of 9.6% during the forecast period 2024-2030.
North American market for Flu RNA Vaccines is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Flu RNA Vaccines is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Flu RNA Vaccines include Sanofi Pasteur Inc., AstraZeneca, CSL Ltd., Abbott, GlaxoSmithKline Plc., Serum Institute of India Pvt. Ltd., Pfizer, BioNTech and F.Hoffman La Roche Ltd, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Flu RNA Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Flu RNA Vaccines.
Report Scope
The Flu RNA Vaccines market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Flu RNA Vaccines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Flu RNA Vaccines manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sanofi Pasteur Inc.
AstraZeneca
CSL Ltd.
Abbott
GlaxoSmithKline Plc.
Serum Institute of India Pvt. Ltd.
Pfizer
BioNTech
F.Hoffman La Roche Ltd
Novartis
Sinnovac Biotech Ltd
Moderna Therapeutics
CureVac
Segment by Type
Non-Replicating mRNA
In Vivo Self-Replicating mRNA
In Vitro Dendritic Cell Non-Replicating mRNA Vaccine
Others
Segment by Application
Hospitals
Vaccination Center
Specialized Clinics
Hospital Pharmacy
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Flu RNA Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Flu RNA Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Flu RNA Vaccines, commonly known as flu vaccines, are designed to protect against the influenza virus. The influenza virus can cause respiratory illnesses ranging from mild to severe, and vaccination is an effective way to prevent or reduce the severity of flu infections.
Flu RNA Vaccines are an important public health measure to prevent the spread of the influenza virus and reduce the risk of severe illness, hospitalization, and death associated with the flu.
The global Flu RNA Vaccines market was valued at US$ 890 million in 2023 and is anticipated to reach US$ 1715.9 million by 2030, witnessing a CAGR of 9.6% during the forecast period 2024-2030.
North American market for Flu RNA Vaccines is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Flu RNA Vaccines is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Flu RNA Vaccines include Sanofi Pasteur Inc., AstraZeneca, CSL Ltd., Abbott, GlaxoSmithKline Plc., Serum Institute of India Pvt. Ltd., Pfizer, BioNTech and F.Hoffman La Roche Ltd, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Flu RNA Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Flu RNA Vaccines.
Report Scope
The Flu RNA Vaccines market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Flu RNA Vaccines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Flu RNA Vaccines manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sanofi Pasteur Inc.
AstraZeneca
CSL Ltd.
Abbott
GlaxoSmithKline Plc.
Serum Institute of India Pvt. Ltd.
Pfizer
BioNTech
F.Hoffman La Roche Ltd
Novartis
Sinnovac Biotech Ltd
Moderna Therapeutics
CureVac
Segment by Type
Non-Replicating mRNA
In Vivo Self-Replicating mRNA
In Vitro Dendritic Cell Non-Replicating mRNA Vaccine
Others
Segment by Application
Hospitals
Vaccination Center
Specialized Clinics
Hospital Pharmacy
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Flu RNA Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Flu RNA Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Flu RNA Vaccines Market Overview
1.1 Product Overview and Scope of Flu RNA Vaccines
1.2 Flu RNA Vaccines Segment by Type
1.2.1 Global Flu RNA Vaccines Market Value Comparison by Type (2024-2030)
1.2.2 Non-Replicating mRNA
1.2.3 In Vivo Self-Replicating mRNA
1.2.4 In Vitro Dendritic Cell Non-Replicating mRNA Vaccine
1.2.5 Others
1.3 Flu RNA Vaccines Segment by Application
1.3.1 Global Flu RNA Vaccines Market Value by Application: (2024-2030)
1.3.2 Hospitals
1.3.3 Vaccination Center
1.3.4 Specialized Clinics
1.3.5 Hospital Pharmacy
1.3.6 Others
1.4 Global Flu RNA Vaccines Market Size Estimates and Forecasts
1.4.1 Global Flu RNA Vaccines Revenue 2019-2030
1.4.2 Global Flu RNA Vaccines Sales 2019-2030
1.4.3 Global Flu RNA Vaccines Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Flu RNA Vaccines Market Competition by Manufacturers
2.1 Global Flu RNA Vaccines Sales Market Share by Manufacturers (2019-2024)
2.2 Global Flu RNA Vaccines Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Flu RNA Vaccines Average Price by Manufacturers (2019-2024)
2.4 Global Flu RNA Vaccines Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Flu RNA Vaccines, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Flu RNA Vaccines, Product Type & Application
2.7 Flu RNA Vaccines Market Competitive Situation and Trends
2.7.1 Flu RNA Vaccines Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Flu RNA Vaccines Players Market Share by Revenue
2.7.3 Global Flu RNA Vaccines Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Flu RNA Vaccines Retrospective Market Scenario by Region
3.1 Global Flu RNA Vaccines Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Flu RNA Vaccines Global Flu RNA Vaccines Sales by Region: 2019-2030
3.2.1 Global Flu RNA Vaccines Sales by Region: 2019-2024
3.2.2 Global Flu RNA Vaccines Sales by Region: 2025-2030
3.3 Global Flu RNA Vaccines Global Flu RNA Vaccines Revenue by Region: 2019-2030
3.3.1 Global Flu RNA Vaccines Revenue by Region: 2019-2024
3.3.2 Global Flu RNA Vaccines Revenue by Region: 2025-2030
3.4 North America Flu RNA Vaccines Market Facts & Figures by Country
3.4.1 North America Flu RNA Vaccines Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Flu RNA Vaccines Sales by Country (2019-2030)
3.4.3 North America Flu RNA Vaccines Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Flu RNA Vaccines Market Facts & Figures by Country
3.5.1 Europe Flu RNA Vaccines Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Flu RNA Vaccines Sales by Country (2019-2030)
3.5.3 Europe Flu RNA Vaccines Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Flu RNA Vaccines Market Facts & Figures by Country
3.6.1 Asia Pacific Flu RNA Vaccines Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Flu RNA Vaccines Sales by Country (2019-2030)
3.6.3 Asia Pacific Flu RNA Vaccines Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Flu RNA Vaccines Market Facts & Figures by Country
3.7.1 Latin America Flu RNA Vaccines Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Flu RNA Vaccines Sales by Country (2019-2030)
3.7.3 Latin America Flu RNA Vaccines Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Flu RNA Vaccines Market Facts & Figures by Country
3.8.1 Middle East and Africa Flu RNA Vaccines Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Flu RNA Vaccines Sales by Country (2019-2030)
3.8.3 Middle East and Africa Flu RNA Vaccines Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Flu RNA Vaccines Sales by Type (2019-2030)
4.1.1 Global Flu RNA Vaccines Sales by Type (2019-2024)
4.1.2 Global Flu RNA Vaccines Sales by Type (2025-2030)
4.1.3 Global Flu RNA Vaccines Sales Market Share by Type (2019-2030)
4.2 Global Flu RNA Vaccines Revenue by Type (2019-2030)
4.2.1 Global Flu RNA Vaccines Revenue by Type (2019-2024)
4.2.2 Global Flu RNA Vaccines Revenue by Type (2025-2030)
4.2.3 Global Flu RNA Vaccines Revenue Market Share by Type (2019-2030)
4.3 Global Flu RNA Vaccines Price by Type (2019-2030)
5 Segment by Application
5.1 Global Flu RNA Vaccines Sales by Application (2019-2030)
5.1.1 Global Flu RNA Vaccines Sales by Application (2019-2024)
5.1.2 Global Flu RNA Vaccines Sales by Application (2025-2030)
5.1.3 Global Flu RNA Vaccines Sales Market Share by Application (2019-2030)
5.2 Global Flu RNA Vaccines Revenue by Application (2019-2030)
5.2.1 Global Flu RNA Vaccines Revenue by Application (2019-2024)
5.2.2 Global Flu RNA Vaccines Revenue by Application (2025-2030)
5.2.3 Global Flu RNA Vaccines Revenue Market Share by Application (2019-2030)
5.3 Global Flu RNA Vaccines Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Sanofi Pasteur Inc.
6.1.1 Sanofi Pasteur Inc. Corporation Information
6.1.2 Sanofi Pasteur Inc. Description and Business Overview
6.1.3 Sanofi Pasteur Inc. Flu RNA Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Sanofi Pasteur Inc. Flu RNA Vaccines Product Portfolio
6.1.5 Sanofi Pasteur Inc. Recent Developments/Updates
6.2 AstraZeneca
6.2.1 AstraZeneca Corporation Information
6.2.2 AstraZeneca Description and Business Overview
6.2.3 AstraZeneca Flu RNA Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.2.4 AstraZeneca Flu RNA Vaccines Product Portfolio
6.2.5 AstraZeneca Recent Developments/Updates
6.3 CSL Ltd.
6.3.1 CSL Ltd. Corporation Information
6.3.2 CSL Ltd. Description and Business Overview
6.3.3 CSL Ltd. Flu RNA Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.3.4 CSL Ltd. Flu RNA Vaccines Product Portfolio
6.3.5 CSL Ltd. Recent Developments/Updates
6.4 Abbott
6.4.1 Abbott Corporation Information
6.4.2 Abbott Description and Business Overview
6.4.3 Abbott Flu RNA Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Abbott Flu RNA Vaccines Product Portfolio
6.4.5 Abbott Recent Developments/Updates
6.5 GlaxoSmithKline Plc.
6.5.1 GlaxoSmithKline Plc. Corporation Information
6.5.2 GlaxoSmithKline Plc. Description and Business Overview
6.5.3 GlaxoSmithKline Plc. Flu RNA Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.5.4 GlaxoSmithKline Plc. Flu RNA Vaccines Product Portfolio
6.5.5 GlaxoSmithKline Plc. Recent Developments/Updates
6.6 Serum Institute of India Pvt. Ltd.
6.6.1 Serum Institute of India Pvt. Ltd. Corporation Information
6.6.2 Serum Institute of India Pvt. Ltd. Description and Business Overview
6.6.3 Serum Institute of India Pvt. Ltd. Flu RNA Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Serum Institute of India Pvt. Ltd. Flu RNA Vaccines Product Portfolio
6.6.5 Serum Institute of India Pvt. Ltd. Recent Developments/Updates
6.7 Pfizer
6.6.1 Pfizer Corporation Information
6.6.2 Pfizer Description and Business Overview
6.6.3 Pfizer Flu RNA Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Pfizer Flu RNA Vaccines Product Portfolio
6.7.5 Pfizer Recent Developments/Updates
6.8 BioNTech
6.8.1 BioNTech Corporation Information
6.8.2 BioNTech Description and Business Overview
6.8.3 BioNTech Flu RNA Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.8.4 BioNTech Flu RNA Vaccines Product Portfolio
6.8.5 BioNTech Recent Developments/Updates
6.9 F.Hoffman La Roche Ltd
6.9.1 F.Hoffman La Roche Ltd Corporation Information
6.9.2 F.Hoffman La Roche Ltd Description and Business Overview
6.9.3 F.Hoffman La Roche Ltd Flu RNA Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.9.4 F.Hoffman La Roche Ltd Flu RNA Vaccines Product Portfolio
6.9.5 F.Hoffman La Roche Ltd Recent Developments/Updates
6.10 Novartis
6.10.1 Novartis Corporation Information
6.10.2 Novartis Description and Business Overview
6.10.3 Novartis Flu RNA Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Novartis Flu RNA Vaccines Product Portfolio
6.10.5 Novartis Recent Developments/Updates
6.11 Sinnovac Biotech Ltd
6.11.1 Sinnovac Biotech Ltd Corporation Information
6.11.2 Sinnovac Biotech Ltd Flu RNA Vaccines Description and Business Overview
6.11.3 Sinnovac Biotech Ltd Flu RNA Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Sinnovac Biotech Ltd Flu RNA Vaccines Product Portfolio
6.11.5 Sinnovac Biotech Ltd Recent Developments/Updates
6.12 Moderna Therapeutics
6.12.1 Moderna Therapeutics Corporation Information
6.12.2 Moderna Therapeutics Flu RNA Vaccines Description and Business Overview
6.12.3 Moderna Therapeutics Flu RNA Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Moderna Therapeutics Flu RNA Vaccines Product Portfolio
6.12.5 Moderna Therapeutics Recent Developments/Updates
6.13 CureVac
6.13.1 CureVac Corporation Information
6.13.2 CureVac Flu RNA Vaccines Description and Business Overview
6.13.3 CureVac Flu RNA Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.13.4 CureVac Flu RNA Vaccines Product Portfolio
6.13.5 CureVac Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Flu RNA Vaccines Industry Chain Analysis
7.2 Flu RNA Vaccines Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Flu RNA Vaccines Production Mode & Process
7.4 Flu RNA Vaccines Sales and Marketing
7.4.1 Flu RNA Vaccines Sales Channels
7.4.2 Flu RNA Vaccines Distributors
7.5 Flu RNA Vaccines Customers
8 Flu RNA Vaccines Market Dynamics
8.1 Flu RNA Vaccines Industry Trends
8.2 Flu RNA Vaccines Market Drivers
8.3 Flu RNA Vaccines Market Challenges
8.4 Flu RNA Vaccines Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Flu RNA Vaccines Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Flu RNA Vaccines Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Flu RNA Vaccines Market Competitive Situation by Manufacturers in 2023
Table 4. Global Flu RNA Vaccines Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Flu RNA Vaccines Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Flu RNA Vaccines Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Flu RNA Vaccines Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Flu RNA Vaccines Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Flu RNA Vaccines, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Flu RNA Vaccines, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Flu RNA Vaccines, Product Type & Application
Table 12. Global Key Manufacturers of Flu RNA Vaccines, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Flu RNA Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Flu RNA Vaccines as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Flu RNA Vaccines Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Flu RNA Vaccines Sales by Region (2019-2024) & (K Units)
Table 18. Global Flu RNA Vaccines Sales Market Share by Region (2019-2024)
Table 19. Global Flu RNA Vaccines Sales by Region (2025-2030) & (K Units)
Table 20. Global Flu RNA Vaccines Sales Market Share by Region (2025-2030)
Table 21. Global Flu RNA Vaccines Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Flu RNA Vaccines Revenue Market Share by Region (2019-2024)
Table 23. Global Flu RNA Vaccines Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Flu RNA Vaccines Revenue Market Share by Region (2025-2030)
Table 25. North America Flu RNA Vaccines Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Flu RNA Vaccines Sales by Country (2019-2024) & (K Units)
Table 27. North America Flu RNA Vaccines Sales by Country (2025-2030) & (K Units)
Table 28. North America Flu RNA Vaccines Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Flu RNA Vaccines Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Flu RNA Vaccines Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Flu RNA Vaccines Sales by Country (2019-2024) & (K Units)
Table 32. Europe Flu RNA Vaccines Sales by Country (2025-2030) & (K Units)
Table 33. Europe Flu RNA Vaccines Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Flu RNA Vaccines Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Flu RNA Vaccines Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Flu RNA Vaccines Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Flu RNA Vaccines Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Flu RNA Vaccines Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Flu RNA Vaccines Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Flu RNA Vaccines Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Flu RNA Vaccines Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Flu RNA Vaccines Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Flu RNA Vaccines Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Flu RNA Vaccines Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Flu RNA Vaccines Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Flu RNA Vaccines Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Flu RNA Vaccines Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Flu RNA Vaccines Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Flu RNA Vaccines Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Flu RNA Vaccines Sales (K Units) by Type (2019-2024)
Table 51. Global Flu RNA Vaccines Sales (K Units) by Type (2025-2030)
Table 52. Global Flu RNA Vaccines Sales Market Share by Type (2019-2024)
Table 53. Global Flu RNA Vaccines Sales Market Share by Type (2025-2030)
Table 54. Global Flu RNA Vaccines Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Flu RNA Vaccines Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Flu RNA Vaccines Revenue Market Share by Type (2019-2024)
Table 57. Global Flu RNA Vaccines Revenue Market Share by Type (2025-2030)
Table 58. Global Flu RNA Vaccines Price (US$/Unit) by Type (2019-2024)
Table 59. Global Flu RNA Vaccines Price (US$/Unit) by Type (2025-2030)
Table 60. Global Flu RNA Vaccines Sales (K Units) by Application (2019-2024)
Table 61. Global Flu RNA Vaccines Sales (K Units) by Application (2025-2030)
Table 62. Global Flu RNA Vaccines Sales Market Share by Application (2019-2024)
Table 63. Global Flu RNA Vaccines Sales Market Share by Application (2025-2030)
Table 64. Global Flu RNA Vaccines Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Flu RNA Vaccines Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Flu RNA Vaccines Revenue Market Share by Application (2019-2024)
Table 67. Global Flu RNA Vaccines Revenue Market Share by Application (2025-2030)
Table 68. Global Flu RNA Vaccines Price (US$/Unit) by Application (2019-2024)
Table 69. Global Flu RNA Vaccines Price (US$/Unit) by Application (2025-2030)
Table 70. Sanofi Pasteur Inc. Corporation Information
Table 71. Sanofi Pasteur Inc. Description and Business Overview
Table 72. Sanofi Pasteur Inc. Flu RNA Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Sanofi Pasteur Inc. Flu RNA Vaccines Product
Table 74. Sanofi Pasteur Inc. Recent Developments/Updates
Table 75. AstraZeneca Corporation Information
Table 76. AstraZeneca Description and Business Overview
Table 77. AstraZeneca Flu RNA Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. AstraZeneca Flu RNA Vaccines Product
Table 79. AstraZeneca Recent Developments/Updates
Table 80. CSL Ltd. Corporation Information
Table 81. CSL Ltd. Description and Business Overview
Table 82. CSL Ltd. Flu RNA Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. CSL Ltd. Flu RNA Vaccines Product
Table 84. CSL Ltd. Recent Developments/Updates
Table 85. Abbott Corporation Information
Table 86. Abbott Description and Business Overview
Table 87. Abbott Flu RNA Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Abbott Flu RNA Vaccines Product
Table 89. Abbott Recent Developments/Updates
Table 90. GlaxoSmithKline Plc. Corporation Information
Table 91. GlaxoSmithKline Plc. Description and Business Overview
Table 92. GlaxoSmithKline Plc. Flu RNA Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. GlaxoSmithKline Plc. Flu RNA Vaccines Product
Table 94. GlaxoSmithKline Plc. Recent Developments/Updates
Table 95. Serum Institute of India Pvt. Ltd. Corporation Information
Table 96. Serum Institute of India Pvt. Ltd. Description and Business Overview
Table 97. Serum Institute of India Pvt. Ltd. Flu RNA Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Serum Institute of India Pvt. Ltd. Flu RNA Vaccines Product
Table 99. Serum Institute of India Pvt. Ltd. Recent Developments/Updates
Table 100. Pfizer Corporation Information
Table 101. Pfizer Description and Business Overview
Table 102. Pfizer Flu RNA Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Pfizer Flu RNA Vaccines Product
Table 104. Pfizer Recent Developments/Updates
Table 105. BioNTech Corporation Information
Table 106. BioNTech Description and Business Overview
Table 107. BioNTech Flu RNA Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. BioNTech Flu RNA Vaccines Product
Table 109. BioNTech Recent Developments/Updates
Table 110. F.Hoffman La Roche Ltd Corporation Information
Table 111. F.Hoffman La Roche Ltd Description and Business Overview
Table 112. F.Hoffman La Roche Ltd Flu RNA Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. F.Hoffman La Roche Ltd Flu RNA Vaccines Product
Table 114. F.Hoffman La Roche Ltd Recent Developments/Updates
Table 115. Novartis Corporation Information
Table 116. Novartis Description and Business Overview
Table 117. Novartis Flu RNA Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Novartis Flu RNA Vaccines Product
Table 119. Novartis Recent Developments/Updates
Table 120. Sinnovac Biotech Ltd Corporation Information
Table 121. Sinnovac Biotech Ltd Description and Business Overview
Table 122. Sinnovac Biotech Ltd Flu RNA Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. Sinnovac Biotech Ltd Flu RNA Vaccines Product
Table 124. Sinnovac Biotech Ltd Recent Developments/Updates
Table 125. Moderna Therapeutics Corporation Information
Table 126. Moderna Therapeutics Description and Business Overview
Table 127. Moderna Therapeutics Flu RNA Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 128. Moderna Therapeutics Flu RNA Vaccines Product
Table 129. Moderna Therapeutics Recent Developments/Updates
Table 130. CureVac Corporation Information
Table 131. CureVac Description and Business Overview
Table 132. CureVac Flu RNA Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 133. CureVac Flu RNA Vaccines Product
Table 134. CureVac Recent Developments/Updates
Table 135. Key Raw Materials Lists
Table 136. Raw Materials Key Suppliers Lists
Table 137. Flu RNA Vaccines Distributors List
Table 138. Flu RNA Vaccines Customers List
Table 139. Flu RNA Vaccines Market Trends
Table 140. Flu RNA Vaccines Market Drivers
Table 141. Flu RNA Vaccines Market Challenges
Table 142. Flu RNA Vaccines Market Restraints
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Flu RNA Vaccines
Figure 2. Global Flu RNA Vaccines Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Flu RNA Vaccines Market Share by Type in 2023 & 2030
Figure 4. Non-Replicating mRNA Product Picture
Figure 5. In Vivo Self-Replicating mRNA Product Picture
Figure 6. In Vitro Dendritic Cell Non-Replicating mRNA Vaccine Product Picture
Figure 7. Others Product Picture
Figure 8. Global Flu RNA Vaccines Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 9. Global Flu RNA Vaccines Market Share by Application in 2023 & 2030
Figure 10. Hospitals
Figure 11. Vaccination Center
Figure 12. Specialized Clinics
Figure 13. Hospital Pharmacy
Figure 14. Others
Figure 15. Global Flu RNA Vaccines Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 16. Global Flu RNA Vaccines Market Size (2019-2030) & (US$ Million)
Figure 17. Global Flu RNA Vaccines Sales (2019-2030) & (K Units)
Figure 18. Global Flu RNA Vaccines Average Price (US$/Unit) & (2019-2030)
Figure 19. Flu RNA Vaccines Report Years Considered
Figure 20. Flu RNA Vaccines Sales Share by Manufacturers in 2023
Figure 21. Global Flu RNA Vaccines Revenue Share by Manufacturers in 2023
Figure 22. The Global 5 and 10 Largest Flu RNA Vaccines Players: Market Share by Revenue in 2023
Figure 23. Flu RNA Vaccines Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 24. Global Flu RNA Vaccines Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 25. North America Flu RNA Vaccines Sales Market Share by Country (2019-2030)
Figure 26. North America Flu RNA Vaccines Revenue Market Share by Country (2019-2030)
Figure 27. U.S. Flu RNA Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. Canada Flu RNA Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. Europe Flu RNA Vaccines Sales Market Share by Country (2019-2030)
Figure 30. Europe Flu RNA Vaccines Revenue Market Share by Country (2019-2030)
Figure 31. Germany Flu RNA Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. France Flu RNA Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. U.K. Flu RNA Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Italy Flu RNA Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Russia Flu RNA Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. Asia Pacific Flu RNA Vaccines Sales Market Share by Region (2019-2030)
Figure 37. Asia Pacific Flu RNA Vaccines Revenue Market Share by Region (2019-2030)
Figure 38. China Flu RNA Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Japan Flu RNA Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. South Korea Flu RNA Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. India Flu RNA Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Australia Flu RNA Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Taiwan Flu RNA Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Indonesia Flu RNA Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Thailand Flu RNA Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Malaysia Flu RNA Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Philippines Flu RNA Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Latin America Flu RNA Vaccines Sales Market Share by Country (2019-2030)
Figure 49. Latin America Flu RNA Vaccines Revenue Market Share by Country (2019-2030)
Figure 50. Mexico Flu RNA Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Brazil Flu RNA Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Argentina Flu RNA Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Middle East & Africa Flu RNA Vaccines Sales Market Share by Country (2019-2030)
Figure 54. Middle East & Africa Flu RNA Vaccines Revenue Market Share by Country (2019-2030)
Figure 55. Turkey Flu RNA Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 56. Saudi Arabia Flu RNA Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 57. U.A.E Flu RNA Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 58. Global Sales Market Share of Flu RNA Vaccines by Type (2019-2030)
Figure 59. Global Revenue Market Share of Flu RNA Vaccines by Type (2019-2030)
Figure 60. Global Flu RNA Vaccines Price (US$/Unit) by Type (2019-2030)
Figure 61. Global Sales Market Share of Flu RNA Vaccines by Application (2019-2030)
Figure 62. Global Revenue Market Share of Flu RNA Vaccines by Application (2019-2030)
Figure 63. Global Flu RNA Vaccines Price (US$/Unit) by Application (2019-2030)
Figure 64. Flu RNA Vaccines Value Chain
Figure 65. Flu RNA Vaccines Production Process
Figure 66. Channels of Distribution (Direct Vs Distribution)
Figure 67. Distributors Profiles
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
